Orange Book product · Generic (ANDA)
RASAGILINE MESYLATE
RASAGILINE MESYLATE
At a glance
Nov 18, 2021
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 18, 2021
4 yr 8 mo ago
Today
Pharmaceutical detail
Active ingredient
RASAGILINE MESYLATE
Strength
EQ 0.5MG BASE
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 201942
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of RASAGILINE MESYLATE
- 2006AZILECTBrand (NDA)
NDA 021641 · TEVA
- 2025RASAGILINE MESYLATEGeneric (ANDA)
ANDA 210150 · TORRENT
- 2024RASAGILINE MESYLATEGeneric (ANDA)
ANDA 208866 · MACLEODS PHARMS LTD
- 2024RASAGILINE MESYLATEGeneric (ANDA)
ANDA 218163 · RISING
- 2019RASAGILINE MESYLATEGeneric (ANDA)
ANDA 206153 · REGCON HOLDINGS
- 2019RASAGILINE MESYLATEGeneric (ANDA)
ANDA 207004 · MICRO LABS
- 2018RASAGILINE MESYLATEGeneric (ANDA)
ANDA 201892 · CHARTWELL RX
- 2017RASAGILINE MESYLATEGeneric (ANDA)
ANDA 201889 · ALKEM LABS LTD
- 2017RASAGILINE MESYLATEGeneric (ANDA)
ANDA 201971 · AUROBINDO PHARMA USA
- 2016RASAGILINE MESYLATEGeneric (ANDA)
ANDA 201970 · ORBION PHARMS
- 2013RASAGILINE MESYLATEGeneric (ANDA)
ANDA 201950 · APOTEX INC
- 2013RASAGILINE MESYLATEGeneric (ANDA)
ANDA 201823 · WATSON LABS INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
